摘要
目的 比较布地格福吸入气雾剂与氟替美维吸入粉雾剂治疗中重度慢性阻塞性肺疾病(COPD)稳定期患者的有效性与安全性。方法 选取安徽省庐江县人民医院2020年3月至2023年2月收治的中重度COPD稳定期患者120例,按随机数字表法分为对照组和研究组,各60例。对照组患者予氟替美维吸入粉雾剂治疗,研究组患者予布地格福吸入气雾剂治疗,两组患者均治疗3个月。结果 研究组和对照组患者的总有效率、不良反应发生率均相当(86.67%比88.33%,11.67%比13.33%,P>0.05)。治疗后,两组患者的肺功能指标第1秒用力呼气容积、用力肺活量、用力肺活量占预计值百分比、第1秒用力呼气容积与用力肺活量的比值均显著升高(P<0.05),但组间无显著差异(P>0.05);两组患者的动脉血气分析指标动脉血氧分压、血氧饱和度均显著升高(P<0.05),动脉血二氧化碳分压均显著降低(P<0.05),但组间均无显著差异(P>0.05);两组患者的疾病相关指标圣乔治呼吸问卷(SGRQ)评分、COPD评估测试量表(CAT)评分均显著降低(P<0.05),6 min步行试验距离均显著延长(P<0.05),但组间均无显著差异(P>0.05);两组患者的炎性因子C反应蛋白、白细胞介素6、降钙素原水平均显著降低(P<0.05),但组间均无显著差异(P>0.05)。结论 布地格福吸入气雾剂与氟替美维吸入粉雾剂治疗中重度COPD稳定期的临床疗效均良好且相当,可有效改善患者的肺功能和动脉血气指标,降低炎性因子水平,且安全性良好,临床应用时应根据患者的疾病特点及使用需求选用。
Objective To compare the efficacy and safety of Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol combined with Fluticasone Furoate,Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation in the treatment of patients with moderate to severe chronic obstructive pulmonary disease(COPD)during stable phase.Methods A total of 120 patients with moderate to severe COPD during stable phase admitted to the Lujiang People's Hospital of Anhui Province from March 2020 to February 2023 were selected and randomly divided into the control group and the study group by the random number table method,with 60 cases in each group.The patients in the control group were treated with Fluticasone Furoate,Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation,while the patients in the study group were treated with Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol.Both groups were treated for three months.Results The total effective rate and incidence of adverse reactions were comparable between the study group and the control group(86.67%vs.88.33%,11.67%vs.13.33%,P>0.05).After treatment,the lung function indexes such as the forced expiratory volume in the first second(FEV1),forced vital capacity(FVC),the percentage of forced vital capacity to estimated value(FVC%),and the FEV1/FVC in the two groups significantly in increased(P<0.05),but there was no significant difference between the two groups(P>0.05);the arterial blood gas analysis indexes of arterial oxygen partial pressure(PaO2)and oxygen saturation(SaO2)in the two groups significantly increased(P<0.05),while the arterial partial pressure of carbon dioxide(PaCO2)in the two groups significantly decreased(P<0.05),but there was no significant difference between the two groups(P>0.05);the disease-related indexes such as the St.George's Respiratory Questionnaire(SGRQ)and COPD Assessment Test(CAT)scores in the two groups significantly decreased(P<0.05),the 6-Minute Walk Test(6MWT)in the two groups significantly extended(P<0.05),but there was no significant difference between the two groups(P>0.05);the levels of inflammatory factors such as C-reactive protein(CRP),interleukin-6(IL-6),and procalcitonin(PCT)in the two groups significantly reduced(P<0.05),but there was no significant difference between the two groups(P>0.05).Conclusion Both Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol combined with Fluticasone Furoate,Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation in the treatment of patients with moderate to severe COPD during stable phase have good and similar clinical efficacy and safety,they can effectively improve lung function and arterial blood gas indexes,and reduce inflammatory factor levels.In clinical practice,the two drugs should be selected based on the patient's disease characteristics and usage needs.
作者
任婷婷
焦伟
丁成红
王梦珂
柯兵
徐丙发
REN Tingting;JIAO Wei;DING Chenghong;WANG Mengke;KE Bing;XU Bingfa(Lujiang People′s Hospital of Anhui Province,Hefei,Anhui,China 231500;The Third Affiliated Hospital of Anhui Medical University,Hefei,Anhui,China 230032)
出处
《中国药业》
CAS
2024年第11期84-87,共4页
China Pharmaceuticals
基金
安徽省自然科学基金[2020085MH267]。
关键词
中重度慢性阻塞性肺疾病
稳定期
布地格福吸入气雾剂
氟替美维吸入粉雾剂
有效性
安全性
moderate to severe chronic obstructive pulmonary disease
stable phase
Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol
Fluticasone Furoate,Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation
efficacy
safety
